期刊文献+

抗血管新生治疗在血液肿瘤治疗中的应用 被引量:1

下载PDF
导出
摘要 血液肿瘤是临床常见的恶性疾病。恶性淋巴瘤、白血病和多发性骨髓瘤都是常见的临床血液肿瘤疾病。抗血管新生治疗是近年来兴起的一种治疗肿瘤的方法,对肿瘤的转移能力和复发具有控制、降低作用。本文主要分析肿瘤微环境,研究抗血管新生治疗常用药物在血液肿瘤临床治疗中的具体应用。
作者 徐媛媛
出处 《中国医药指南》 2014年第25期83-84,共2页 Guide of China Medicine
  • 相关文献

参考文献6

二级参考文献81

  • 1Ferrara N.Vascular endothelial growth factor[J].Arterioscler Thromb Vasc Biol,2009,29(6):789-791.
  • 2寿成超,董志伟.抗血管生成与肿瘤治疗[C].第四届中国肿瘤学术大会教育集,2006:150-156.
  • 3Batchelor TT,Sorensen AG,di Tomaso E,et al.AZD2171,a pan-VEGF receptor tyrosine kinase inhibitor,normalizes tumor vasculature and alleviates edema in glioblastoma patients[J].Cancer Cell,2007,11(1):83-95.
  • 4Kamoun WS,Ley CD,Farrar CT,et al.Edema control by cediranib,a vascular endothelial growth factor receptor-targeted kinase inhibitor,prolongs survival despite persistent brain tumor growth in mice[J].J Clin Oncol,2009,27(15):2542-2552.
  • 5Willett CG,Duda DG,di Tomaso E,et al.Efficacy,safety and biomarkers of neoadjuvant bevacizumab,radiation therapy,and 5-Fluorouracil in rectal cancer:a multidisciplinary phase II study[J].J Clin Oncol,2009,27(18):3020-3026.
  • 6Heymach JV,Hanrahan EO,Mann H,et al.Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC[J].J Clin Oncol,2008,26(Suppl):a8009.
  • 7Burstein HJ,Chen YH,Parker LM,et al.VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy[J].Clin Cancer Res,2008,14(23):7871-7877.
  • 8Dowlati A,Gray R,Sandler AB,et al.Cell adhesion molecules,vascular endothelial growth factor,and basic fibroblast growth factor in patients with nonsmall cell lung cancer treated with chemotherapy with or without bevacizumab an Eastern Cooperative Oncology Group study[J].Clin Cancer Res,2008,14(5):1407-1412.
  • 9Tannir NM,Zurita AJ,Heymach JV,et al.A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa:Clinical results and biomarker analysis[J].J Clin Oncol,2008,26(Suppl):a5093.
  • 10Rini BI,Michaelson MD,Rosenberg JE,et al.Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma[J].J Clin Oncol,2008,26(22):3743-3748.

共引文献30

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部